secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001829126-26-001634
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin announces pivotal HALO Clarity trial for insomnia to support FDA de novo submission
--------------------------------------------------------------------------------

- 150-patient, triple-blinded, sham-controlled randomized study via decentralized NeuroCare virtual clinic with Lindus Health.
- Designed to support planned FDA de novo submission for moderate to severe insomnia treatment.
- Builds on prior published 120-patient study showing significant sleep improvements with no adverse effects.
- Targets $multi-billion insomnia market; ~30M U.S. adults seek drug-free options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626001634/0001829126-26-001634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626001634/nexalintec_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-001634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer